+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia

Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia

Blood 98(1): 241-243

The small molecule receptor tyrosine kinase (RTK) inhibitor SU5416 targets the vascular endothelial growth factor receptor 2 and the stem cell factor receptor c-kit. Herein is described the successful treatment of a 65-year-old woman with SU5416, in second relapse of acute myeloid leukemia (AML) and refractory toward standard chemotherapy regimens. After 12 weeks of treatment with SU5416, the blast cell counts (blood and bone marrow) decreased to undetectable levels and the peripheral blood cell counts normalized with the exception of the platelet count (50-80 x 10(9)/L [50-80 x 10(3)/microL]). The duration of the remission is longer than 4 months during maintenance therapy with SU5416. Microvessel density in the patient's bone marrow dropped from 33.4 to 12.3 microvessels/x500-field 8 weeks after SU5416 administration and remains in the normal range. This is the first report of a stable remission achieved after administration of the RTK inhibitor SU5416 in a patient with AML relapse.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 011393555

Download citation: RISBibTeXText

PMID: 11418488

Related references

Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions. Seminars in Oncology 27(4 Suppl 8): 25-33, 2000

SU5416, a novel angiogenesis inhibitor in colorectal cancer and other advanced malignancies. Cancer Investigation 18(Suppl. 1): 40-41, 2000

Effects of STZ-induced diabetes and its treatment with vanadyl sulphate on cyclosporine A-induced nephrotoxicity in rats. Archives of Toxicology 79(9): 493-499, 2005

Ajoene (natural garlic compound): a new anti-leukaemia agent for Aml therapy. Leukemia Research 28(7): 667-671, 2004

SU5416 sensitizes ovarian cancer cells to cisplatin through inhibition of nucleotide excision repair. CMLS Cellular and Molecular Life Sciences 60(4): 794-802, 2003

SU5416, a novel receptor tyrosine kinase inhibitor, in the treatment of patients with refractory, c-kit positive, acute myeloid leukemia. Blood 98(11 Part 1): 124a, 2001

Phase II clinical trials in oncology Recommendations for choice of planification methods. Proceedings of the American Association for Cancer Research Annual Meeting (41): 35-36, 2000

Complete remission after CBT high dose chemotherapy in metastatic breast cancer patients Impact on overall survival and progression free survival. Breast Cancer Research and Treatment 57(1): 66, 1999

Tyrosine kinase inhibitor therapy for systemic sclerosis: Quo Vadis?. Arthritis and Rheumatism 63(11): 3199-3203, 2011

JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. Clinical Cancer Research 15(22): 6841-6851, 2009

The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Research 61(8): 3369-3372, 2001

Development of Pgrac100-based expression vectors allowing high protein production levels in Bacillus subtilis and relatively low basal expression in Escherichia coli. Microbial Cell Factories 14: 72, 2015

Sustained combustion of an animal carcass and its implications for the consumption of human bodies in fires. Journal of Forensic Sciences 46(5): 1076-1081, 2001

Treatment with a topical glucocorticoid, budesonide, reduced the variability of rhinomanometric nasal airway resistance. Rhinology 52(1): 19-24, 2014

Philadelphia-negative acute myeloid leukemia with new chromosomal abnormalities developing after first-line imatinib treatment for chronic phase chronic myeloid leukemia. American Journal of Hematology 83(9): 755, 2008